A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease
Public ClinicalTrials.gov record NCT05280548. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Open-label, Parallel-group, 18-month Phase 3 Study to Evaluate the Effect of Venglustat Compared With Usual Standard of Care on Left Ventricular Mass Index in Participants With Fabry Disease and Left Ventricular Hypertrophy
Study identification
- NCT ID
- NCT05280548
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Sanofi
- Industry
- Enrollment
- 104 participants
Conditions and interventions
Conditions
Interventions
- Venglustat (GZ402671) Drug
- Agalsidase alfa Drug
- Agalsidase beta (GZ419828) Drug
- Migalastat Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 2, 2022
- Primary completion
- May 21, 2026
- Completion
- Dec 5, 2027
- Last update posted
- Jun 23, 2026
2022 – 2027
United States locations
- U.S. sites
- 8
- U.S. states
- 8
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama -The Kirklin Clinic- Site Number : 8400010 | Birmingham | Alabama | 35233 | — |
| University of California Los Angeles Medical Center- Site Number : 8400008 | Los Angeles | California | 90095 | — |
| Emory University School of Medicine - Atlanta- Site Number : 8400009 | Atlanta | Georgia | 30322 | — |
| Ann & Robert H. Lurie Children's Hospital of Chicago- Site Number : 8400005 | Chicago | Illinois | 60611 | — |
| Maryam Banikazemi, MD- Site Number : 8400001 | Hawthorne | New York | 10532 | — |
| Renal Disease Research Institute- Site Number : 8400012 | Dallas | Texas | 75204 | — |
| University of Utah Health Hospital- Site Number : 8400006 | Salt Lake City | Utah | 84132 | — |
| Lysosomal and Rare Disorders Research and Treatment Center (LDRTC)- Site Number : 8400004 | Fairfax | Virginia | 22030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 46 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05280548, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 23, 2026 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05280548 live on ClinicalTrials.gov.